Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70013 | 0.82 | TYR (0.66) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL4984449 | 0.79 | TYR (0.48) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL31745134 | 0.77 | ESR1 (0.47) | TP53CYP3A4 | |
| SCHEMBL8764373 | 0.76 | TYR (0.63) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL5654220 | 0.76 | TYR (0.67) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL27643967 | 0.76 | TYR (0.47) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL4370686 | 0.75 | TYR (0.81) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL8444198 | 0.75 | TYR (0.65) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL31536236 | 0.75 | TYR (0.65) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL10404683 | 0.74 | TYR (0.65) | TYRMEN1TP53CYP3A4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541454-B2 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20050159606-A1 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2005040357-A2 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | EPOCH BIOSCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159606-A1 | Compounds and methods for fluorescent labeling | TFEB, HLCS, PFAS | TYR 1222/4885MEN1 1387/4885TP53 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.